The original FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial in 3533 patients with type 2 diabetes and CKD found subcutaneous semaglutide 1 mg once weekly reduced the risk of the primary kidney endpoint (at least a 50% decline of estimated glomerular filtration rate, kidney failure or kidney or cardiovascular death) by 24% and all-cause death by 20%
Any uninsured patient considering long-term GLP-1 therapy should undergo baseline metabolic and renal assessment
GHKCu has been shown to stimulate collagen production, glycosaminoglycan synthesis, and extracellular matrix remodeling key pathways in skin health, firmness, and elasticity and modulates the activity of enzymes involved in tissue repair
Melanotan 1 Dosage Data from past studies shows that MT-1 has typically been administered twice per day
BPC 157 powder is a synthetic peptide composed of 15 amino acids, derived from a protective protein in human gastric juice
The novel, focused Dysbiosis Index included in the GI360 was developed and validated in a clinical setting, utilizing research-based methodology to discern dysbiosis vs